Skip to main navigation
Close
Main navigation
Advocacy
Issue Overview
#Rx4StateSavings
#4GRxANTED
#MarkupMadness
State Advocacy
GDUFA/BsUFA User Fees
Biosimilars Council
Action Center
Our Impact
Join
About Us
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Social Commitment
Careers
Contact Us
Stories
Events
Resources
All Resources
Drug Shortages White Paper
2023 Savings Report
Supply Chain Blueprint
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Press Releases
Blog
Founders Blogs
Amicus Briefs
Take Action
Menu
New White Paper
- Read AAM Report on Drug Shortages
Learn More
Close
Breadcrumb
Association for Accessible Medicines
Resources
Resources
Share
Find up-to-date information on generics and biosimilars
Filter Resources
Issues
Biosimilar User Fee Act (BsUFA)
Biosimilars
Complex Generics
Drug Approval Process (GDUFA)
Drug Prices
Drug Shortages
Generic Drug Labeling
Generic Supply Chain
IP Issues
Low Income Subsidies (LIS in Part D)
Medicaid
Medicare
NAFTA
Patent Reform
Patient Stories
Pharmaceutical Waste Take Back
Preventing Drug Abuse
Quality
REMS/Sample Acquisition Remedies
State Initiatives
Tariffs
Trade
Transparency
User Fees
Resource Type
Blog
Amicus Brief
Press Release
Infographic
Video
Report
Fact Sheet
Presentation
Press Release
Mar 7, 2023
| Susan Reilly
AAM Statement on President Biden's Budget Plan
Blog
Feb 24, 2023
| Erica Klinger
A Look Back at Access! 2023
Press Release
Feb 21, 2023
| Susan Reilly
AAM Announces 2023 Associate Members
Press Release
Feb 16, 2023
| Susan Reilly
AAM Announces 2023 Board of Directors
Press Release
Feb 15, 2023
| Susan Reilly
AAM Statement on CMMI Report
Press Release
Feb 15, 2023
| Susan Reilly
New Social Media Campaign Unveiled to Raise Awareness of the Essential Role of Generic Medicine in Americans’ Lives
Video
Feb 14, 2023
| Erica Klinger
A Fireside Chat with AAM Chair, Christine Baeder and Mark Cuban, Entrepreneur and Cost Plus founder.
Press Release
Feb 13, 2023
| Susan Reilly
Christine Baeder Named Chair of the Association for Accessible Medicines Board of Directors
Blog
Feb 9, 2023
| Jonathan Kimball
The Quickest Route to U.S. Essential Medicines Production: Existing and Idle Production Sites
Press Release
Jan 30, 2023
| Susan Reilly
AAM Applauds CMS for Requiring Health Plans to Place Generic Drugs On Generic Tiers
Fact Sheet
Jan 26, 2023
| Erica Klinger
AAM Opposes HF17 and SF168 Which Won’t Bring Down Drug Prices for Minnesota Patients
Press Release
Jan 23, 2023
| Susan Reilly
Study Finds Middlemen Increasingly Block Patient Access to New Generics
Load More
Advocacy
Issue Overview
#Rx4StateSavings
#4GRxANTED
#MarkupMadness
State Advocacy
GDUFA/BsUFA User Fees
Biosimilars Council
Action Center
Our Impact
Join
About Us
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Social Commitment
Careers
Contact Us
Stories
Events
GRx+Biosims 2022
Access! 2022
Resources
All Resources
Drug Shortages White Paper
2023 Savings Report
Supply Chain Blueprint
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Press Releases
Blog
Founders Blogs
Amicus Briefs
Take Action